NCT06528418 Identification of Multiple Pulmonary Diseases Using Volatile Organic Compounds Biomarkers in Human Exhaled Breath
| NCT ID | NCT06528418 |
| Status | Recruiting |
| Phase | — |
| Sponsor | ChromX Health |
| Condition | Lung Cancer |
| Study Type | OBSERVATIONAL |
| Enrollment | 10,000 participants |
| Start Date | 2024-06-30 |
| Primary Completion | 2026-12-30 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 10,000 participants in total. It began in 2024-06-30 with a primary completion date of 2026-12-30.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The goal of this observational study is to develop an advanced expiratory algorithm model utilizing exhaled breath volatile organic compound (VOC) marker molecules. This model aims to accurately diagnose mutiple pulmonary diseases. The primary objectives it strives to accomplish are: 1. To assess the diagnostic accuracy of an exhaled breath VOC-assisted diagnostic artificial intelligence (AI) model in diagnose several common pulmonary diseases. 2. To assess the diagnostic accuracy of an exhaled breath VOC-assisted diagnostic artificial intelligence (AI) model in diagnose more pulmonary diseases.
Eligibility Criteria
Inclusion Criteria: * Males or females, age must be 18 years old or above. * Patients must meet the CT imaging diagnostic criteria for different lung diseases, and patients must be able to provide electronic versions of CT image data. * Patients must have a clear clinical diagnosis. * All participants must sign a written informed consent form. Exclusion Criteria: * Pregnant women. * Individuals with a history of cancer other than lung disease. * Individuals who have undergone organ transplants or non-autologous (allogeneic) bone marrow or stem cell transplants. * Individuals with other severe organic diseases or mental illnesses. * Individuals with metabolic diseases such as diabetes, hyperlipidemia, etc. * Any other condition that researchers deem unsuitable for participation in this clinical trial.
Contact & Investigator
Jianxing He, MD
STUDY CHAIR
The First Affiliated Hospital of Guangzhou Medical University
Frequently Asked Questions
Who can join the NCT06528418 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, up to 100 Years, studying Lung Cancer. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06528418 currently recruiting?
Yes, NCT06528418 is actively recruiting participants. Contact the research team at hengrui_liang@163.com for enrollment information.
Where is the NCT06528418 trial being conducted?
This trial is being conducted at Guangzhou, China.
Who is sponsoring the NCT06528418 clinical trial?
NCT06528418 is sponsored by ChromX Health. The principal investigator is Jianxing He, MD at The First Affiliated Hospital of Guangzhou Medical University. The trial plans to enroll 10,000 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.